Merck to buy Prometheus Biosciences for about $11 billion
Merck has agreed to acquire Prometheus Biosciences for about $10.8 billion to bolster the company's presence in immunology, the companies said on Sunday.
Source link
- Top Wall Street analysts say buy these stocks amid the latest macroeconomic uncertainty
- Will Turkey’s elections finally spell the end of Recep Tayyip Erdoğan? – The Guardian
